Apramycin

DB04626

small molecule experimental vet_approved

Deskripsi

Apramycin is an aminoglycoside antibiotic and has a bactericidal action against many gram-negative bacteria. Apramycin is a structurally unique antibiotic that contains a bicyclic sugar moiety and a monosubstituted deoxystreptamine. It is not approved for use in humans.

Struktur Molekul 2D

Berat 539.5771
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

868 Data
Succinylcholine The therapeutic efficacy of Succinylcholine can be increased when used in combination with Apramycin.
Metocurine iodide The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Apramycin.
Gallamine triethiodide The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Apramycin.
Cisatracurium Apramycin may increase the neuromuscular blocking activities of Cisatracurium.
Rocuronium The therapeutic efficacy of Rocuronium can be increased when used in combination with Apramycin.
Atracurium besylate The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Apramycin.
Doxacurium The therapeutic efficacy of Doxacurium can be increased when used in combination with Apramycin.
Mivacurium The therapeutic efficacy of Mivacurium can be increased when used in combination with Apramycin.
Decamethonium The therapeutic efficacy of Decamethonium can be increased when used in combination with Apramycin.
Metocurine The therapeutic efficacy of Metocurine can be increased when used in combination with Apramycin.
Pancuronium The therapeutic efficacy of Pancuronium can be increased when used in combination with Apramycin.
Pipecuronium The therapeutic efficacy of Pipecuronium can be increased when used in combination with Apramycin.
Vecuronium The therapeutic efficacy of Vecuronium can be increased when used in combination with Apramycin.
Rapacuronium The therapeutic efficacy of Rapacuronium can be increased when used in combination with Apramycin.
Pyrantel The therapeutic efficacy of Pyrantel can be increased when used in combination with Apramycin.
Neosaxitoxin The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Apramycin.
Atracurium The therapeutic efficacy of Atracurium can be increased when used in combination with Apramycin.
Gallamine The therapeutic efficacy of Gallamine can be increased when used in combination with Apramycin.
Alcuronium The therapeutic efficacy of Alcuronium can be increased when used in combination with Apramycin.
Tubocurarine The therapeutic efficacy of Tubocurarine can be increased when used in combination with Apramycin.
Carboplatin The risk or severity of ototoxicity and nephrotoxicity can be increased when Apramycin is combined with Carboplatin.
Foscarnet The risk or severity of nephrotoxicity can be increased when Apramycin is combined with Foscarnet.
Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Apramycin.
Tenofovir disoproxil Apramycin may increase the nephrotoxic activities of Tenofovir disoproxil.
Tenofovir alafenamide Apramycin may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir Apramycin may increase the nephrotoxic activities of Tenofovir.
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Apramycin.
Zoledronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Apramycin is combined with Zoledronic acid.
Alendronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Apramycin is combined with Alendronic acid.
Ibandronate The risk or severity of nephrotoxicity and hypocalcemia can be increased when Apramycin is combined with Ibandronate.
Clodronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Apramycin is combined with Clodronic acid.
Risedronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Apramycin is combined with Risedronic acid.
Etidronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Apramycin is combined with Etidronic acid.
Incadronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Apramycin is combined with Incadronic acid.
Pamidronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Apramycin is combined with Pamidronic acid.
Tiludronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Apramycin is combined with Tiludronic acid.
Cyclosporine The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Apramycin.
Icosapent The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Apramycin.
Cefotiam The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Apramycin.
Mesalazine The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Apramycin.
Cefmenoxime The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Apramycin.
Cefmetazole The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Apramycin.
Indomethacin The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Apramycin.
Cidofovir The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Apramycin.
Triamterene The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Apramycin.
Cefpiramide The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Apramycin.
Ceftazidime The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Apramycin.
Loracarbef The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Apramycin.
Framycetin The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Apramycin.
Cefalotin The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Apramycin.
Nabumetone The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Apramycin.
Ketorolac The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Apramycin.
Tenoxicam The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Apramycin.
Celecoxib The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Apramycin.
Cefotaxime The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Apramycin.
Tolmetin The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Apramycin.
Rofecoxib The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Apramycin.
Piroxicam The risk or severity of nephrotoxicity can be increased when Piroxicam is combined with Apramycin.
Methotrexate The risk or severity of nephrotoxicity can be increased when Methotrexate is combined with Apramycin.
Cephalexin The risk or severity of nephrotoxicity can be increased when Cephalexin is combined with Apramycin.
Fenoprofen The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Apramycin.
Valaciclovir The risk or severity of nephrotoxicity can be increased when Valaciclovir is combined with Apramycin.
Valdecoxib The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Apramycin.
Diclofenac The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Apramycin.
Sulindac The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Apramycin.
Bacitracin The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Apramycin.
Amphotericin B The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Apramycin.
Cephaloglycin The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Apramycin.
Flurbiprofen The risk or severity of nephrotoxicity can be increased when Flurbiprofen is combined with Apramycin.
Adefovir dipivoxil The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Apramycin.
Pentamidine The risk or severity of nephrotoxicity can be increased when Pentamidine is combined with Apramycin.
Etodolac The risk or severity of nephrotoxicity can be increased when Etodolac is combined with Apramycin.
Mefenamic acid The risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Apramycin.
Acyclovir The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Apramycin.
Naproxen The risk or severity of nephrotoxicity can be increased when Naproxen is combined with Apramycin.
Sulfasalazine The risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Apramycin.
Phenylbutazone The risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Apramycin.
Meloxicam The risk or severity of methemoglobinemia can be increased when Apramycin is combined with Meloxicam.
Carprofen The risk or severity of nephrotoxicity can be increased when Carprofen is combined with Apramycin.
Cefaclor The risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Apramycin.
Diflunisal The risk or severity of nephrotoxicity can be increased when Diflunisal is combined with Apramycin.
Tacrolimus The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Apramycin.
Ceforanide The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Apramycin.
Salicylic acid The risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Apramycin.
Meclofenamic acid The risk or severity of nephrotoxicity can be increased when Meclofenamic acid is combined with Apramycin.
Acetylsalicylic acid The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Apramycin.
Oxaprozin The risk or severity of nephrotoxicity can be increased when Oxaprozin is combined with Apramycin.
Hydrochlorothiazide The risk or severity of nephrotoxicity can be increased when Hydrochlorothiazide is combined with Apramycin.
Ketoprofen The risk or severity of nephrotoxicity can be increased when Ketoprofen is combined with Apramycin.
Balsalazide The risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Apramycin.
Ibuprofen The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Apramycin.
Cefditoren The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Apramycin.
Atazanavir The risk or severity of nephrotoxicity can be increased when Atazanavir is combined with Apramycin.
Colistimethate The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Apramycin.
Cefuroxime The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Apramycin.
Cefapirin The risk or severity of nephrotoxicity can be increased when Cefapirin is combined with Apramycin.
Cefadroxil The risk or severity of nephrotoxicity can be increased when Cefadroxil is combined with Apramycin.
Cefprozil The risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Apramycin.
Ceftriaxone The risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Apramycin.
Olsalazine The risk or severity of nephrotoxicity can be increased when Apramycin is combined with Olsalazine.

Target Protein

16S ribosomal RNA

Referensi & Sumber

Synthesis reference: Koji Tomita, Hiroshi Tsukiura, Hiroshi Kawaguchi, "Fermentation process for producing apramycin and nebramycin factor V'." U.S. Patent US4032404, issued December, 1974.
Artikel (PubMed)
  • PMID: 17258916
    Hermann T, Tereshko V, Skripkin E, Patel DJ: Apramycin recognition by the human ribosomal decoding site. Blood Cells Mol Dis. 2007 May-Jun;38(3):193-8. Epub 2007 Jan 29.
  • PMID: 16596680
    Kondo J, Francois B, Urzhumtsev A, Westhof E: Crystal structure of the Homo sapiens cytoplasmic ribosomal decoding site complexed with apramycin. Angew Chem Int Ed Engl. 2006 May 12;45(20):3310-4.
  • PMID: 15849690
    Han Q, Zhao Q, Fish S, Simonsen KB, Vourloumis D, Froelich JM, Wall D, Hermann T: Molecular recognition by glycoside pseudo base pairs and triples in an apramycin-RNA complex. Angew Chem Int Ed Engl. 2005 Apr 29;44(18):2694-700.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul